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Abstract
Background: Loss of Amylo-alpha-1-6-glucosidase-4-alpha-glucanotransferase (AGL) drives rapid proliferation of
bladder cancer cells by upregulating Hyaluronic acid(HA) Synthase (HAS2) mediated HA synthesis. However the role
of HA receptors CD44 and Hyaluronan Mediated Motility Receptor (RHAMM) in regulating the growth of bladder
cancer cells driven by loss of AGL has not been studied.
Methods: Western blot analysis and Terminal deoxynucleotidyl transferase (TdT) dUTP Nick-End Labeling (TUNEL)
assay was carried out to study cellular apoptosis with HAS2, CD44 and RHAMM loss in bladder cancer cells with and
without AGL expression. Proliferation and softagar assays were carried out to study cellular anchorage dependent and
independent growth. Clinicopathologic analysis was carried out on bladder cancer patient datasets.
Results: Higher amounts of cleaved Cas3, Cas9 and PARP was observed in AGL low bladder cancer cell with loss of
HAS2, CD44 or RHAMM. TUNEL staining showed more apoptotic cells with loss of HAS2, CD44 or RHAMM in AGL low
bladder cancer cells. This revealed that bladder cancer cells whose aggressive growth is mediated by loss of AGL are
susceptible to apoptosis with loss of HAS2, CD44 or RHAMM. Interestingly loss of either CD44 or RHAMM induces
apoptosis in different low AGL expressing bladder cancer cell lines. Growth assays showed that loss of CD44 and
RHAMM predominantly inhibit anchorage dependent and independent growth of AGL low bladder cancer cells.
Clinicopathologic analysis revealed that high RHAMM mRNA expression is a marker of poor patient outcome in
bladder cancer and patients with high RHAMM and low AGL tumor mRNA expression have poor survival.
Conclusion: Our findings strongly point to the importance of the HAS2-HA-CD44/RHAMM pathway for rapid
growth of bladder cancer cells with loss of AGL and provides rational for targeting this pathway at various steps
for “personalized” treatment of bladder cancer patients based of their AGL expression status.
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ase (AGL) and glycogen phosphorylase (PYG) isoforms
are responsible for glycogen breakdown (glycogenoly-
sis) in humans [1]. Inactivation of AGL leads to buildup
of abnormal glycogen in the liver, heart and skeletal
muscle leading to Glycogen Storage Disease III (GSD
III) [2, 3], a condition with good prognosis when
treated by high protein and complex carbohydrate diet
[2]. We have identified AGL as a tumor growth sup-
pressor and prognostic marker in human bladder can-
cer, for the first time showing AGL plays a role in
cancer biology [4].
We have identified that AGL’s role in tumor biology
is independent of its enzymatic activity and is not due
to changes in glycogenolysis [4]. We have further
identified that loss of AGL promotes rapid cancer cell
proliferation dependent on extracellular glucose,
Serine Hydroxymethyltransferase 2 (SHMT2) driven
glycine synthesis and Hyaluronic Acid (HA) Synthase
2 (HAS2) mediated HA synthesis [4, 5]. Using genetic
manipulation and chemical inhibition of HA synthesis
we have demonstrated that HAS2 dependent HA syn-
thesis is a major driven of tumor growth with AGL
loss [5].
HA is known to interact with many cell surface pro-
teins to activate downstream signaling pathways [6].
CD44 and Hyaluronan Mediated Motility Receptor
(RHAMM) are the two major cell surface proteins HA
bind to trigger downstream signaling which promotes
tumor growth and metastasis [6–8]. Here we aim to
study the role of CD44 and RHAMM, downstream of
HA, in rapid growth of bladder cancer cells driven by
low AGL expression. We identified that loss of either
CD44 or RHAMM induce apoptosis in specific low AGL
bladder cancer cell lines. CD44 and RHAMM both play
a role in inhibiting anchorage dependent and independent
growth of bladder cancer cells with low AGL expression.
We also identified that RHAMM mRNA expression alone
and in combination with AGL mRNA expression serves as
a prognostic marker in bladder cancer.
Methods
Cell line and biochemical reagents
UMUC3, T24T and MGHU4 control (shCTL) and AGL
(shAGL) depleted human bladder cancer cells were, cul-
tured and used as described [4, 5]. AGL knockdown in
these were achieved using shRNA TRCN0000035082
(Sigma-Aldrich) as described previously [4, 5]. These three
bladder cancer cell lines were chosen for the study because
they show an induction in growth with AGL loss, hence
serve as good model cell lines to study AGL biology in
bladder cancer [4, 5]. 4-Methylumbelliferone (4-MU, cat. #
M1508-10G) was obtained from Sigma-Aldrich. HA (cat. #
GLR001) was obtained from R&D systems (Minneapolis,
MN). siRNA sequences 5’-GGTTTGTGATTCAGACACT-
3’ was used at a concentration of 50nM to knockdown
HAS2 (siHAS2) as previously reported [5]. siGENOME
SMARTpool siRNAs were used to knockdown CD44
(M-009999-03-0005, siCD44) and RHAMM (M-010409-
01-0005, siRHAMM) at a concentration of 20nM. siRNA’s
were purchased from Dharmacon (Lafayette, CO) and
transfected using Lipofectamine RNAiMAX (Invitrogen)
using manufacturer instructions. A second siRNA se-
quence 5’-GCAGATCGATTTGAATATA-3’ for CD44
(siCD44-2) and 5’-GAGCTCAAATCAAGAATAT-3’ for
RHAMM (siRHAMM-2), purchased from Dharmacon
(Lafayette, CO), were also used at a concentration of
20nM to knockdown CD44 and RHAMM respectively
using above mentioned protocol. A non-specific siRNA
(siCTL, 5′-CGTACGCGGAATACTTCGA-3′) was used
as control for all the experiments. Human bladder cancer
cell lines UMUC3, T24T and MGHU4 were authenticated
by the University of Colorado PPSR core using an Applied
Biosystems Profiler Plus Kit which analyzed 9 STR loci
(Life Technologies 4303326). After authentication cells
were frozen within 1–2 weeks. Vials of cells were resusci-
tated less than 2 months prior to being used in experi-
ments in this study.
PCR and western blot
HAS2 mRNA expression was determined by the ΔΔCT
method [4, 5] with GAPDH as control for human blad-
der cancer cell lines. Expression was normalized to cells
transduced with control plasmid (shCTL) transfected
with control siRNA (siCTL) to determine HAS2 gene
expression and knockdown in control (shCTL) and
AGL knockdown (shAGL) cells with HAS2 siRNA
treatment. When shAGL cells were transfected with
control siRNA or siRNA specific to CD44 or RHAMM,
HAS2 gene expression was determined by normalizing
to shAGL cells transfected with siCTL. HAS 2 primer:
forward 5’- TCCCGGTGAGACAGATGAGT-3’ reverse
5’ GGCTGGGTCAAGCATAGTGT-3’; GAPDH primer:
forward 5’-TCTTTTGCGTCGCCAGCCGA 3’ reverse
5’- ACCAGGCGCCCAATACGACC-3’ were used for
the RT-PCR experiments.
Antibodies used for westerns were anti-AGL
(Agrisera, Vannas, Sweden) and anti- α tubulin
(Calbiochem, San Diego, CA), Actin (GeneTex, Irvine,
CA), CD44 (Cell Signaling), RHAMM (Abcam,
Cambridge, MA), apoptotic antibody sampler kit (Cell
Signaling), ERK (Cell Signaling), p-ERK (Cells Signaling),
DR5 (Cell Signaling) and Fas (Cell Signaling). HRP
(Cell Signaling) labeled mouse or rabbit secondary anti-
bodies were used chemiluminescence using ECL
(Pierce, Rockford, IL).
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Terminal deoxynucleotidyl transferase (TdT) dUTP
Nick-End Labeling (TUNEL) Assay
shCTL and shAGL bladder cancer cells were plated in
chambered slides and treated with control siRNA or
siRNA against HAS2, CD44 or RHAMM. 48 h after
transfection TUNEL assay was carried out using Dead-
End™ Colorimetric TUNEL System from Promega fol-
lowing manufacturer instruction. Images of cells taken
using Olympus IX71 microscope at a magnification of
40X. Images were analyzed and quantified using ImageJ.
Anchorage dependent and independent proliferation
Anchorage dependent and independent proliferation
was measured as before [4, 9]. Briefly, shCTL and
shAGL bladder cancer cells were transfected with con-
trol siRNA or siRNA targeting CD44 or RHAMM. 72 h
after transfection anchorage-independent growth was
assessed by plating cells in 0.4 % agar in triplicate. Col-
onies were stained with Nitro-BT (Sigma) and counted
using Image J. Cell proliferation and viability was
assessed by plating 103 cells per well in 96-well plates
in triplicate for proliferation studies. CyQUANT® Cell
Proliferation Assay (Thermo Fisher Scientific) was car-
ried out according to manufacturer instruction to
measure cell proliferation.
HA ELISA
Fresh media is applied 48 h after CD44 or RHAMM
siRNA transfection in shAGL cells followed by HA
analysis by ELISA 24 h later. HA ELISA was con-
ducted as per manufacturer instructions using TECO®
HA ELISA kit.
Immunofluorescence
UMUC3 and T24T cells with and without AGL expres-
sion were plated in chambered slides. 24 h later cells
were washed with PBS, fixed with 4 % paraformaldehyde,
permealized with 0.2 % Triton X-100, blocked with 1 %
bovine serum albumin (BSA) followed by treatment with
anti-RHAMM antibody (Cat no. 185728, Abcam, Cam-
bridge, MA). Secondary antibody used was tagged with
Alexa Fluor 488 Nfrom Thermo Fisher Scientific. Slides
were mounted with ProLong(R) Diamond Antifade
Mountant with DAPI (Thermo Fisher Scientific). Images
of cells taken using Olympus IX71 microscope at a mag-
nification of 40X.
Patient and statistical analysis
Patient microarray and clinicopathologic information of
patient datasets [10, 11] is shown in Additional file 1:
Table S1. Raw microarray data were processed and nor-
malized by the Robust Multi-array Average algorithm
implemented in the affy package in R [12]. In case of
multiple probe sets for one gene, the probe with the
highest mean expression across all samples was selected
to represent the gene’s expression. Gene expression dif-
ferences between two groups of samples (tumor vs. nor-
mal, high grade vs. low grade, and muscle invasive (MI)
vs. non-muscle invasive tumors (NMI)) were tested by
Wilcoxon rank sum tests. Associations of categorical
gene expression with survival were examined by Cox
proportional hazards models and logrank tests. Data
from in vitro experiments were analyzed by 2-tailed
Student t-test with unequal variances. Error bars denote
standard deviation of the mean as indicated. "n" in the
Figure Legends represents the number of replicates for a
particular sample.
Results
Inhibition of HA synthesis induce apoptosis in low AGL
bladder cancer cells
HA is known to induce tumor growth and metastasis by
interacting with its two main receptors CD44 and
RHAMM [7, 8]. Earlier studies have shown that inhib-
ition of HA synthesis results in reduction of CD44 and
RHAMM expression, and also leads to cellular apoptosis
[13, 14]. We have earlier shown that loss of AGL induces
rapid growth of bladder cancer cells via HAS2 mediated
HA synthesis [5]. Here we study the role of HA’s two
main receptors in bladder cancer growth driven by low
AGL expression. Bladder cancer cells UMUC3 and
T24T cells with (shCTL) and without (shAGL) AGL was
used in this study. These bladder cancer cells transduced
with control shRNA (shCTL) and shRNA against AGL
(shAGL) has been used by us in previous research pro-
jects [4, 5]. We have previously demonstrated knock-
down of HAS2 reduces HA synthesis predominantly in
shAGL cells [5]. Here HAS2 was knocked down in
UMUC3 and T24T shCTL and shAGL cells using the
same siRNA against HAS2 (siHAS2) used previously [5].
We observed higher HAS2 expression in UMUC3 and
T24T shAGL cells (Fig. 1a, b) as reported previously and
the siHAS2 reduces its expression in the shCTL and
shAGL bladder cancer cells (Fig. 1a, b).
Interestingly loss of HAS2 does not reduce expres-
sion of CD44 and RHAMM in bladder cancer cells irre-
spective of AGL expression status (Fig. 1c, e). 4MU, a
well-known inhibitor of HA synthesis, has been shown
by us to inhibit HA synthesis and growth of bladder
cancer cells driven by loss of AGL [5]. 4MU, like
HAS2, has been shown to reduce CD44 and RHAMM
receptor expression in cancer cells [13]. We treated
UMUC3 and T24T shCTL and shAGL cells with
500 μM 4MU, a concentration at which it reduces HA
synthesis. However 4MU treatment did not have a
major impact on the expression of CD44 and RHAMM
in UMUC3 or T24T shCTL and shAGL cells
(Additional file 1: Figure S1). Next we added low
Oldenburg et al. BMC Cancer  (2016) 16:713 Page 3 of 12
molecular weight hyaluronic acid (LMW HA, 15–
40 kDa) at a concentration of 50 and 100 μg/ml on the
above mentioned cells. LMW HA at 100 μg/ml partially
rescued the growth inhibition caused by 4MU treat-
ment of AGL knockdown bladder cancer cells [5].
Treatment with superfluous amounts of LMW HA had
little impact on CD44 and RHAMM expression of
UMUC3 and T24T bladder cancer cells irrespective of
AGL expression status (Additional file 1: Figure S2).
These experiments show that loss of HA synthesis by
genetic alteration (inhibition of HAS2 expression) or by
an inhibitor (4MU) or addition of superfluous HA have
little effect on CD44 and RHAMM expression in
UMUC3 and T24T bladder cancer cells.
Next we looked into cellular apoptotic pathway with
loss of HAS2 in bladder cancer cells with and without
AGL. SiHAS2 predominantly induced apoptosis of
UMUC3 shAGL cells as shown by higher levels of
cleaved PARP, Cas9 and Cas3 (Fig. 1c, d). In T24T cells
loss of HAS2 induced apoptosis in both shCTL and
shAGL cells but induction of apoptosis was higher in
shAGL cells as observed by higher levels of cleaved
PARP, Cas9 and Cas3 (Fig. 1e, f ). These experiments





















































































































































































































































































































































































Fig. 1 HAS2 loss and apoptosis in bladder cancer cells +/− AGL. a, b qRT-PCR demonstrating efficacy of HAS2 depletion in UMUC3 and T24T
control (shCTL) and AGL knockdown (shAGL) cells. Cells were plated and 24 h later transfected with scrambled (siCTL) or directed siRNA against
HAS2 (siHAS2). Details of siRNA used are in Materials and Methods. Cells were harvested at 48 h for mRNA followed by qRT-PCR analysis (n = 3).
c 48 h after UMUC3 shCTL and shAGL cells were transfected with scrambled siRNA (siCTL) or siRNA against HAS2 (siHAS2), cells were lysed and
expression of CD44, RHAMM and the proteins involved in the apoptotic pathway were detected by Western blot. d Densitometric analysis of cleaved
apoptotic proteins normalized to total protein and the UMUC3 shCTL siCTL sample (n = 3). e 48 h after T24T shCTL and shAGL were transfected with
scrambled siRNA (siCTL) or siRNA against HAS2 (siHAS2), cells were lysed and expression of CD44, RHAMM and the proteins involved in the apoptotic
pathway were detected by Western blot. f Densitometric analysis of cleaved apoptotic proteins normalized to total protein and the T24T shCTL siCTL
sample (n = 3). Results are shown as mean ± SD, *P < 0.05
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cells are vulnerable to apoptosis on inhibition of HA
synthesis.
Loss of either CD44 or RHAMM Induce apoptosis in low
AGL expressing bladder cancer cells
It has been shown that inhibition of HA signaling induce
apoptosis by activating Death receptor signaling [13, 15].
Since loss of HAS2 induced apoptosis predominantly in the
rapid growing shAGL bladder cancer cells we decided to
investigate whether loss of the two dominant HA receptor
CD44 and RHAMM, result in similar apoptotic induction
of shAGL bladder cancer cells. We knocked down CD44
and RHAMM individually in UMUC3 and T24T cells with
and without AGL to study their role in apoptosis. Knock-
down of CD44 using siGENOME SMARTpool siRNA
(siCD44) was able to induces Death Receptor 5 (DR5)
expression followed by apoptotic signaling in UMUC3
shAGL cells as seen by increased levels of cleaved PARP,
Cas9 and Cas3 (Fig. 2a, b). Fas has also been shown as
an inducer of apoptosis with inhibition of HA signaling
[13, 15], however we did not see any increase in Fas ex-
pression with CD44 loss (Fig. 2a, b). Interestingly loss
of CD44 did not induce DR5 or apoptotic signaling in
T24T bladder cancer cells with or without AGL expres-
sion. The experiments were repeated using a second
siRNA (siCD44-2) against CD44. SiCD44-2 also induced
apoptosis only in UMUC3 shAGL cells (Additional file 1:
Figure S3). Similarly genetic knockdown of RHAMM
using siGENOME SMARTpool siRNA (siRHAMM) was
carried out in UMUC3, T24T shCTL and shAGL cells.
Surprisingly knockdown of RHAMM induced DR5 ex-
pression and apoptotic signaling predominantly in T24T
Fig. 2 CD44 loss and apoptosis in bladder cancer cells +/− AGL. a UMUC3 shCTL and shAGL cells were plated and 24 h later transfected with
scrambled siRNA (siCTL) or siGENOME SMARTpool siRNA against CD44(siCD44). Details of siRNA are in Material and Methods. Cells were lysed
48 h after transfection and Western blot was carried out for proteins involved in apoptosis. b Densitometric analysis of cleaved apoptotic proteins
normalized to total protein and the UMUC3 shCTL siCTL sample (n = 3). DR5 and Fas normalized to Actin and the UMUC3 shCTL siCTL sample
(n = 3). Results are shown as mean ± SD, *P < 0.05. c T24T shCTL and shAGL cells were plated and 24 h later transfected with scrambled siRNA
(siCTL) or siGENOME SMARTpool siRNA against CD44 (siCD44). Details of siRNA are in Material and Methods. Cells were lysed 48 h after transfection and
Western blot was carried out for proteins involved in apoptosis. d Densitometric analysis of cleaved apoptotic proteins normalized to total protein and
the T24T shCTL siCTL sample (n = 3). DR5 and Fas normalized to Actin and the shCTL siCTL sample (n = 3). Results are shown as mean ± SD, *P < 0.05
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shAGL cells and not in UMUC3 shCTL or shAGL cells
(Fig. 3). A second siRNA against RHAMM (siRHAMM-2)
yielded similar results (Additional file 1: Figure S4).
Since loss of either CD44 or RHAMM induced apop-
tosis in the two different shAGL bladder cancer cells
(UMUC3 and T24T respectively) used, we decided to in-
clude a third cell line into our study. MGHU4 bladder
cancer cells, with loss of AGL, have shown rapid growth
driven by the HAS2/HA axis [5]. Knockdown of RHAMM
and not CD44 induced apoptosis in MGHU4 shAGL cells
as seen by increased levels of c-Cas3 (Additional file 1:
Figure S5). Thus showing that loss of RHAMM is a major
inducer of apoptotic signaling in bladder cancer cells
driven by AGL loss.
RHAMM is known to have different function based of
its cellular localization [16, 17]. HA is known to regulate
RHAMM function irrespective of its cellular localization
[16–19]. Immunofluorescence analysis showed that in
UMUC3 shCTL cells RHAMM expression is predomin-
antly cytoplasmic (Additional file 1: Figure S6A). How-
ever UMUC3 shAGL cells have RHAMM staining
pattern which suggest it is localizes with microtubules
and fluorescent punctas in the nuclear region suggesting
its dominant presence in the centrosomes (Additional
file 1: Figure S6A) [18, 20, 21]. This shows in UMUC3
cells, there is a major change in RHAMM localization
with AGL loss. A previous study have shown that HA
treatment can result in RHAMM localization to nucleus
and centrosomes [18]. We speculate that increase in HA
synthesis with AGL loss is driving RHAMM to localize
with microtubules and centrosomes in UMUC3 cells,
where it is involved in cell division and do not induce
apoptosis when the protein is genetically inhibited. In
T24T cells irrespective of AGL expression status,
RHAMM is present predominantly in the cytoplasm and
also in the centrosomes as suggested by the fluorescent
Fig. 3 RHAMM loss and apoptosis in bladder cancer cells +/− AGL. a UMUC3 shCTL and shAGL cells were plated and 24 h later transfected with
scrambled siRNA (siCTL) or siGENOME SMARTpool siRNA against RHAMM (siRHAMM). Details of siRNA are in Material and Methods. Cells were
lysed 48 h after transfection and Western blot was carried out for proteins involved in apoptosis. b Densitometric analysis of cleaved apoptotic
proteins normalized to total protein and the UMUC3 shCTL siCTL sample (n = 3). DR5 and Fas normalized to Actin and the UMUC3 shCTL siCTL
sample (n = 3). Results are shown as mean ± SD, *P < 0.05. c T24T shCTL and shAGL cells were plated and 24 h later transfected with scrambled
siRNA (siCTL) or siGENOME SMARTpool siRNA against RHAMM (siRHAMM). Details of siRNA are in Material and Methods. Cells were lysed 48 h
after transfection and Western blot was carried out for proteins involved in apoptosis. d Densitometric analysis of cleaved apoptotic proteins
normalized to total protein and the T24T shCTL siCTL sample (n = 3). DR5 and Fas normalized to Actin and the UMUC3 shCTL siCTL sample
(n = 3). Results are shown as mean ± SD, *P < 0.05
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punctas in the nucleus of some cells (Additional file 1:
Figure S6B). We think loss of RHAMM results in apop-
tosis of AGL knockdown cells when it is present in the
cytoplasm as seen in T24T shAGL cells.
Since RHAMM is known to activate ERK by directly
interacting with it or by activating MAPK signaling path-
way by interacting with cell surface receptors [16, 17] we
looked into activated ERK in UMUC3 and T24T shCTL
and shAGL cells. There was no significant difference in
ERK activation in these cells with and without AGL (Add-
itional file 1: Figure S6C, D). Loss of RHAMM reduced
ERK activation in both UMUC3 and T24T shCTL and
shAGL cells (Additional file 1: Figure S6C, D), suggesting
cellular localization of RHAMM did not impact ERK acti-
vation and downstream signaling driven by ERK in these
bladder cancer cells.
We further looked into HAS2 expression and HA syn-
thesis in UMUC3 and T24T shAGL cells with CD44 and
RHAMM loss. In UMUC3 shAGL cells loss of CD44 in-
duced apoptosis (Fig. 2a, b) and also majorly inhibited
HAS2 expression and HA synthesis (Additional file 1:
Figure S7A, C) where as in T24T shAGL cells loss of
RHAMM induced apoptosis (Fig. 3c, d) and was
responsible for greater reduction of HAS2 expression
and HA synthesis (Additional file 1: Figure S7B, D).
These outcomes illustrate that specific AGL knockdown
bladder cancer cell lines undergo apoptosis with inhib-
ition of either CD44 or RHAMM and loss of this par-
ticular HA receptor also inhibit HA synthesis by a
feedback mechanism. This also provides evidence that
CD44 and RHAMM are involved in HAS2/HA signaling
in bladder cancer cells with loss of AGL.
After observing an increase in cleaved caspases with
loss of HAS2, CD44 or RHAMM in UMUC3 and T24T
shAGL cells, we carried out TUNEL assay to detect
the % of cells undergoing apoptosis. Since an increase in
cleaved caspases can also be a result of a few cells undergo-
ing apoptosis with a stronger biochemical apoptotic signal-
ing. UMUC3, T24T shCTL and shAGL cells were subjected
to TUNEL staining 48 h after transfection with siHAS2,
siCD44 or siRHAMM. Quantification of the TUNEL stain
showed that 35 to 40 % (P < 0.05) UMUC3 shAGL cells
undergoes apoptosis with loss of HAS2 and CD44.
RHAMM knockdown has no impact on apoptosis of
UMUC3 shAGL cells (Fig. 4a, b). These results are consist-
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Fig. 4 TUNEL assay to detect apoptosis with HAS2, CD44 or RHAMM loss in bladder cancer cells +/− AGL. a, b UMUC3 and T24T shCTL and
shAGL cells were plated in chambered slides and 24 h later transfected with scrambled siRNA or siRNA against HAS2 (siHAS2), CD44 (siCD44) or
RHAMM (siRHAMM). Details of siRNA are in Material and Methods. 48 h after transfection cells were subjected to TUNEL assay according to
manufacturer protocol as mentioned in Material and Methods. Images were taken at a 40X magnification using Olympus IX71 microscope.
c, d Quantification of TUNEL staining in UMUC3 and T24T shCTL and shAGL cells with the different gene knockdowns (n = 3). TUNEL staining
quantified using ImageJ. Results are shown as mean ± SD, *P < 0.05
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showed loss of RHAMM did not induce death recep-
tor and apoptotic signaling in UMUC3 shAGL cells
(Figs. 2 and 3). Less than 10 % UMUC3 shCTL cells
underwent apoptosis with loss of HAS2, CD44 or
RHAMM (Fig. 4b). These observations along with our
previous work show that parental UMUC3 cells are
not vulnerable to inhibition of HAS2/HA-CD44-
RHAMM signaling, whereas loss of AGL makes these
cells depend on HA signaling.
Our experiments with T24T bladder cancer cells show
that 15 to 18 % of T24T shCTL and shAGL cells
undergo apoptosis with loss of HAS2 (Fig. 4c, d). Bio-
chemical apoptotic signaling showed that T24T shAGL
cells had higher levels of cleaved PARP, Cas9 and Cas3
compared to T24T shCTL cells with HAS2 knockdown
(Fig. 1). This suggests that T24T shAGL cells are under-
going a stronger biochemical apoptotic signaling indi-
cated by higher levels of cleaved proteins but the actual
number of cells undergoing apoptosis is the same as
T24T shCTL cells. Loss of RHAMM induced signifi-
cantly higher (P < 0.05) apoptosis in T24T shAGL cells
compared to shCTL cells (Fig. 4c, d) which is consistent
with the previously observed apoptotic signaling which
showed loss of RHAMM induced death receptor and
apoptotic cell signal predominantly in T24T shAGL cells
(Figs. 2 and 3). CD44 loss did not impact apoptosis of
T24T shCTL or shAGL cells (Fig. 4c, d), since death re-
ceptor and apoptotic signaling was not induced with
CD44 knockdown in T24T cells +/− AGL expression
(Figs. 2 and 3).
Loss of CD44 and rhamm inhibit growth of bladder
cancer cells driven by loss of AGL
Loss of AGL promotes anchorage dependent and inde-
pendent growth of bladder cancer cells [4]. Here we ex-
plore the role of CD44 and RHAMM in the rapid
growth of bladder cancer cells mediated by AGL loss.
UMUC3, T24T shCTL and shAGL cells were plated for
anchorage dependent and independent growth assay
72 h after knockdown of CD44 or RHAMM using siR-
NAs. The cells were trypsinized 72 h after the siRNA
transfections, counted and replated for the anchorage
dependent and independent growth assays. Thus we got
rid of the cells which have undergone apoptosis in the
growth assay, since the maximum apoptosis was ob-
served 48 h after gene knockdown. In UMUC3 cells loss
of CD44 and RHAMM reduced the anchorage
dependent proliferation of shCTL and shAGL cells
(Fig. 5a, b) where as in T24T cells loss of CD44 and
RHAMM only reduced the proliferation of shAGL cells
(Fig. 5c, d). We also introduced MGHU4 cells in our
study. Loss of CD44 and RHAMM reduces the anchor-
age dependent proliferation of MGHU4 shAGL cells
(Additional file 1: Figure S8). Similarly in anchorage
independent growth assay loss of CD44 or RHAMM
reduced the growth of both UMUC3 shCTL and
shAGL cells (Fig. 5e) however only reduced the growth
of T24T shAGL cells (Fig. 5f ). CD44 and RHAMM
regulate numerous downstream proliferative signaling
pathways [18, 22, 23]. These experiments suggest that
the proliferative pathways driven by CD44 and
RHAMM are important for anchorage independent and
dependent growth of some bladder cancer cells
(UMUC3) irrespective of AGL expression status but in
others (T24T and MGHU4), there proliferative path-
ways are more important for the fast growing AGL
knockdown cells. These experiments imply that
increase in HA synthesis with AGL loss results in
increased CD44 and RHAMM dependent proliferative
signaling in T24T and MGHU4 shAGL cells.
The relevance of AGL, CD44 and RHAMM in human
bladder cancer
We investigated into RHAMM, CD44 mRNA as a
prognostic marker in bladder cancer. CD44 mRNA is
not differentially expressed between muscle and non-
muscle invasive tumors in two independent patient
datasets [10, 11] (Fig. 6a). However mRNA expression
of CD44 is low in high grade tumors with P = 0.01 in
one of the two independent datasets studied (Fig. 6a).
High RHAMM mRNA expression was observed in high
grade and muscle invasive disease in two independent
patient datasets with significant P value (Fig. 6b). Ana-
lysis of patient overall survival shows that low CD44
expression tends to poor overall survival of bladder
cancer patients in Kim et al. [10] dataset (Fig. 6ci),
however the data is not statistically significant (HR = 0.61,
P = 0.07). A similar analysis showed high mRNA expres-
sion of RHAMM predicts poor overall survival for bladder
cancer patients (HR = 1.71, P = 0.03; Fig. 6cii) in Kim et al.
[10] dataset. These experiments suggest that high CD44
mRNA expression is not a predictor of poor bladder can-
cer patient outcome even though CD44 is an important
contributor in tumor growth and metastasis.
Since high RHAMM expression is a predictor of poor
outcome in bladder cancer patients, we examined the
utility of combining AGL and RHAMM expression in
stratifying bladder patient outcome. The primary object-
ive here was to determine if such expression levels could
eventually be used to identify the optimal patient cohort
who may be enrolled in future clinical trials with inhibi-
tors of RHAMM or HA signaling. The secondary object-
ive was to lead credence to the hypothesis that AGL
affects tumor biology by RHAMM downstream of
HAS2/HA axis as well as other effectors such as
SHMT2 [4]. Kaplan-Meier survival using the same cut-
offs as for individual RHAMM (Fig. 6cii) and AGL also
revealed a significant stratification of survival but with a
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somewhat better HR of 2.47 (Fig. 6ciii). Importantly, this
analysis indicated that combining these two variables en-
hanced the magnitude of the stratification as measured
by the HR compared to using either variable alone.
Discussion
We have previously established that loss of AGL drives
aggressive bladder cancer growth via HAS2 mediated
HA synthesis and provided preclinical evidence that tar-
geting the HAS2/HA axis is possibly therapeutically
beneficial for bladder cancer patients with low AGL ex-
pression [5]. HA interacts with numerous cell surface
proteins [6]. Of these, CD44 and RHAMM have been
extensively studied in cancer biology [7]. It is well
known that downstream signaling prompted by CD44
and RHAMM on interaction with HA is crucial for HA
mediated tumor growth and metastasis in various tumor
types including bladder [24–27].
Here we focus on the importance of CD44 and
RHAMM in driving the rapid growth of bladder cancer
cells with low AGL expression. The aim of the study was
to identify if aggressive bladder tumor growth mediated
by AGL loss depends on either CD44 or RHAMM or
both. This would point to new therapeutic avenue for
bladder cancer patients based of their AGL expression
levels. We used established bladder cancer cell lines in
our experiments to test our hypothesis followed by ana-
lysis of bladder cancer patient samples to emphasize the
clinical relevance of our work. Our study resulted in






























































































































































































Fig. 5 Anchorage dependent and independent growth with CD44 or RHAMM loss in bladder cancer cells +/− AGL. a–d 72 h after UMUC3 or T24T
shCTL and shAGL were transfected with siCTL, siCD44 or siRHAMM, they were plated for monolayer growth (n = 6) in 96-welled plate (103 cells/well)
for 5 days followed by CyQUANT assay. e, f 72 h after UMUC3 or T24T shCTL and shAGL were transfected with siRNA against CD44 (siCD44) or RHAMM
(siRHAMM) they were plated in agar for evaluation of anchorage independent growth (15x103 cells/well) in 6 well plate (n = 3). Results are shown as
mean ± SD, *P < 0.05
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Previous studies have reported that genetic or chem-
ical inhibition of HA synthesis by knockdown of the
HAS enzymes or treatment with 4MU results in de-
crease of CD44 and RHAMM protein expression [6, 7,
28] which has been used as a readout of HA based cell
signaling inhibition. However it is not known how in-
hibition of HA synthesis regulate CD44 and RHAMM
expression. Interestingly when we knocked down
HAS2 or treated with 4MU, UMUC3 and T24T bladder
cancer cells +/− AGL expression had no change in their
CD44 and RHAMM expression. Addition of superfluous
amounts of HA to these cells did not impact CD44 and
RHAMM expression. However knockdown of CD44
and RHAMM did reduce HAS2 expression and HA
synthesis in UMUC3 and T24T shAGL cells providing
evidence that there HA receptors are involved in
HAS2/HA signaling in the rapid growing shAGL cells.
Moreover knockdown of HAS2, CD44 and RHAMM
reduced growth and induced apoptosis predominantly
in the AGL knockdown bladder cancer cells confirming
that loss of AGL drives bladder cancer growth via















































Fig. 6 Relationship of CD44, RHAMM and AGL mRNA to clinicopathologic variables in human bladder cancer. a, b CD44 and RHAMM mRNA
expression in high grade (HG) and muscle invasive (MI) bladder tumors compared to low grade (LG) and non-muscle invasive (NMI) bladder tumors in
two independent patient datasets (i) Stransky et al. [11] and (ii) Kim et al. [10] (Additional file 1: Table S1). c Kaplan Meier analysis of categorized (high/
low) mRNA levels of i) CD44; ii) RHAMM and iii) AGL and RHAMM and overall survival in the Kim et al. [10] bladder patient dataset. Hazard Ratios (HR)
and logrank P values are shown. High- and low-expression groups were determined by an optimal cutoff that gave the best p-value and was selected
from nine different percentiles (from 10th to 90th). The optimal cutoff was 20th percentile for CD44, 60th percentile for RHAMM and 30th percentile
for AGL
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that reduction in CD44 or RHAMM protein expression
with inhibition of HA synthesis is not always a deter-
minant of HA signal inhibition.
It has been reported that CD44 and RHAMM can
interact independently with HA to induce certain cel-
lular behavior and in certain cases their interaction
have redundant and overlapping functions [22]. We
observed something similar in rapid growing bladder
cancer cells driven by AGL loss. We observed loss of
either CD44 or RHAMM is important for induction of
apoptosis in specific AGL low bladder cancer cell line.
We observed loss of CD44 induced apoptosis in
UMUC3 shAGL cells whereas loss of RHAMM in-
duced apoptosis in T24T and MGHU4 shAGL cells.
Apoptosis in these cells was induced by death receptor
signaling as implied by increase in DR5 expression.
These observations illustrate with AGL knockdown, in
some bladder cancer cell lines (UMUC3) inhibition of
HA-CD44 interaction, whereas in others (T24T and
MGHU4) inhibition of HA-RHAMM interaction is
important for induction of death receptor signaling
and apoptosis. Change is cellular location of RHAMM
with AGL loss in some bladder cancer cell lines
(UMUC3) could be a determining factor on how this
protein functions. However the reason behind altered
RHAMM localization and function with AGL loss in
only UMUC3 bladder cell lines is not clear and needs
to be investigated. Detailed investigation is required to
understand how death receptor signaling and apop-
tosis is triggered by either CD44 or RHAMM knock-
down in rapid growing bladder cancer cells driven by
AGL loss. However HA interaction with CD44 and
RHAMM has identical effect on bladder cancer cell
growth. Anchorage dependent and independent prolif-
eration assay showed that loss of both CD44 and
RHAMM inhibited growth of bladder cancer cells
driven by AGL loss. This demonstrates that HA inter-
action with both CD44 and RHAMM gives rise to
similar proliferative signaling in the AGL low bladder
cancer cells. The mechanism how CD44 and RHAMM
drives growth of bladder cancer cells that have lost
AGL will be investigated in future.
Inhibitors of CD44 and RHAMM are being tested for
cancer treatment with a few inhibitors in clinical trials
[7]. However severe side effects due to their effects on
normal cells and the immune system have been a major
hindrance for drugs targeting CD44 and RHAMM [7]. It
is clear for the success of drugs targeted at CD44 and
RHAMM it is important to identify the subset of pa-
tients whose tumor are highly dependent on CD44 and
RHAMM for growth. We propose that bladder cancer
patients with low AGL expression are an ideal subset of
cancer patients who can be treated with CD44 and
RHAMM inhibitors.
Conclusion
Our previous study and current research have looked in
detail into the involvement of HA signaling for aggressive
growth of bladder cancer cells driven by AGL loss. We
have established that loss of AGL promotes rapid bladder
cancer growth via HAS2-HA-CD44/RHAMM pathway.
Thus we conclude that inhibition of this pathway at vari-
ous points can be beneficial for personalized treatment of
bladder cancer patients with low AGL expression.
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and T24T cells +/− AGL. Figure S5. Effect of CD44 and RHAMM loss on
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